The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Aclaris Therapeutics, Inc. | COM | 00461U105 | 6,155 | 951,384 | SH | SOLE | 951,384 | 0 | 0 | ||
| ALX Oncology Holdings Inc. | COM | 00166B105 | 83,917 | 973,514 | SH | SOLE | 973,514 | 0 | 0 | ||
| Cymabay Therapeutics, Inc. | COM | 23257D103 | 10,258 | 1,787,094 | SH | SOLE | 1,787,094 | 0 | 0 | ||
| Cytokinetics Incorporated | COM | 23282W605 | 29,840 | 1,435,992 | SH | SOLE | 1,435,992 | 0 | 0 | ||
| Generation Bio Co. | COM | 37148K100 | 24,323 | 857,939 | SH | SOLE | 857,939 | 0 | 0 | ||
| Keros Therapeutics, Inc. | COM | 492327101 | 99,652 | 1,412,705 | SH | SOLE | 1,412,705 | 0 | 0 | ||
| Kinnate Biopharma Inc. | COM | 49705R105 | 384,738 | 9,671,643 | SH | SOLE | 9,671,643 | 0 | 0 | ||
| Kura Oncology, Inc. | COM | 50127T109 | 59,049 | 1,807,982 | SH | SOLE | 1,807,982 | 0 | 0 | ||
| Nurix Therapeutics, Inc. | COM | 67080M103 | 77,196 | 2,347,804 | SH | SOLE | 2,347,804 | 0 | 0 | ||
| Olema Pharmaceuticals, Inc. | COM | 68062P106 | 39,331 | 818,030 | SH | SOLE | 818,030 | 0 | 0 | ||
| Relay Therapeutics, Inc. | COM | 75943R102 | 88,913 | 2,139,380 | SH | SOLE | 2,139,380 | 0 | 0 | ||
| Therapeutics Acquisition Corp | COM CL A | 88339T103 | 4,872 | 350,000 | SH | SOLE | 350,000 | 0 | 0 | ||
| Vaxcyte, Inc. | COM | 92243G108 | 12,377 | 465,821 | SH | SOLE | 465,821 | 0 | 0 | ||